NEO-MEDROL ACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEO-MEDROL ACETATE (NEO-MEDROL ACETATE).
Methylprednisolone acetate is a corticosteroid with glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression, suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes), and inhibition of immune cell proliferation and function.
| Metabolism | Hepatic metabolism primarily via CYP3A4; also undergoes extrahepatic metabolism. Metabolites are inactive or weakly active. |
| Excretion | Primarily renal: ~75-90% as metabolites and <5% unchanged. Biliary/fecal: ~10-25%. |
| Half-life | Terminal half-life approximately 24-36 hours; prolonged in hepatic impairment; sufficient for once-daily dosing. |
| Protein binding | Approximately 90-95%, primarily bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Approximately 0.5-1.0 L/kg; indicates extensive tissue distribution, including synovial fluid and joint spaces. |
| Bioavailability | Intra-articular/local injection: nearly 100% locally; oral: not applicable (parenteral only). |
| Onset of Action | Intra-articular, intralesional, soft tissue: within 24-48 hours; systemic effects may be delayed due to local depot effect. |
| Duration of Action | Intra-articular: 1-4 weeks (depends on dose and joint size); systemic duration up to 36-48 hours after single dose. |
| Molecular Weight | 416.51 |
Intra-articular, intrabursal, or periarticular injection: 4-40 mg depending on joint size. For intralesional injection: 10-40 mg per lesion. For systemic use (intramuscular): 40-120 mg every 1-5 weeks as needed.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustment required for renal impairment; use with caution in severe renal impairment due to potential fluid retention and increased risk of adrenal suppression. GFR-based modifications not established. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Use with caution; consider dose reduction by 25-50% due to reduced metabolism. Child-Pugh C: Avoid use or use lowest effective dose with close monitoring. |
| Pediatric use | Intra-articular: 4-20 mg depending on joint size and age. Intralesional: 10-20 mg per lesion. Systemic IM: 0.5-2 mg/kg every 1-4 weeks, titrated to response. Maximum single IM dose: 120 mg. |
| Geriatric use | Use lowest effective dose (e.g., 4-20 mg intra-articularly or 40-80 mg IM). Monitor for hyperglycemia, osteoporosis, and infection risk. Avoid prolonged use. Dexamethasone suppression test may be unreliable. |
| 1st trimester | Corticosteroids including methylprednisolone acetate are associated with increased risk of cleft palate in animal studies; use only if benefit outweighs risk. |
| 2nd trimester | May cause fetal growth restriction and adrenal suppression; use only if clearly needed. |
| 3rd trimester | May cause fetal adrenal suppression; avoid prolonged use near term. |
Clinical note
Comprehensive clinical and safety monograph for NEO-MEDROL ACETATE (NEO-MEDROL ACETATE).
| Placental transfer | Methylprednisolone acetate crosses the placenta; the active metabolite methylprednisolone is metabolized by placental 11β-HSD2, but significant transfer occurs at high doses. |
| Breastfeeding | Methylprednisolone is excreted into breast milk in low amounts. At maternal doses up to 80 mg/day, levels are unlikely to cause adverse effects in nursing infants. However, monitor for potential growth suppression or adrenal suppression. |
■ FDA Black Box Warning
No FDA black box warning specifically for NEO-MEDROL ACETATE. However, corticosteroids in general carry warnings for increased risk of infection, adrenal suppression, and Cushing's syndrome.
| Serious Effects |
Systemic fungal infectionsHypersensitivity to methylprednisolone or componentsImmunization with live vaccines
| Precautions | Increased susceptibility to infections; adrenal suppression; Cushing's syndrome; osteoporosis; gastrointestinal perforation; psychiatric disturbances; fluid and electrolyte imbalances; growth suppression in children; use in patients with herpes simplex keratitis, recent GI surgery, or untreated systemic infections. |
| Food/Dietary | No clinically significant food interactions. Avoid excessive alcohol consumption as it may increase corticosteroid side effects. |
Loading safety data…
| Lactation Rating | L2 - Limited data; probably compatible. |
| Teratogenic Risk | Corticosteroids like NEO-MEDROL ACETATE (methylprednisolone acetate) are associated with an increased risk of cleft palate, intrauterine growth restriction, and adrenal suppression in neonates when used during pregnancy, particularly in the first trimester. Risk is dose and duration dependent. Use only if clearly needed, weighing benefit versus risk. |
| Fetal Monitoring | Monitor maternal blood glucose, blood pressure, weight gain, and signs of infection. In fetus, assess growth by ultrasound (4-6 weekly) ; monitor for intrauterine growth restriction. Newborns should be evaluated for adrenal insufficiency if maternal exposure was prolonged or high dose. |
| Fertility Effects | Corticosteroids may suppress endogenous cortisol and disrupt hypothalamic-pituitary-gonadal axis, potentially causing menstrual irregularities and impaired fertility. Taper to lowest effective dose when considering conception. |
| Clinical Pearls | NEO-MEDROL ACETATE is a combination of neomycin (aminoglycoside antibiotic) and methylprednisolone acetate (corticosteroid). For otic use only; do not use in eyes or for injection. Contraindicated in perforated tympanic membrane due to risk of ototoxicity. Shake well before use. Limit use to 10 days to avoid superinfection or masking of infection. |
| Patient Advice | For external ear use only. Do not put in eyes or swallow. · Shake the bottle well before each use. · Apply 3-4 drops into the affected ear 3-4 times daily, or as directed. · Do not use for more than 10 days unless instructed by your doctor. · Do not use if you have a perforated eardrum or ear tube. · Avoid getting water in the ear during treatment; use a cotton ball when showering. · Tell your doctor if you have diabetes, tuberculosis, or a fungal/viral ear infection. |